South Korean Biotech Company Soars in Debut to Become $8 Billion Stock
(Bloomberg) -- SK Biopharmaceuticals Co., a biotechnology arm of SK Group in South Korea, surged to more than double the company's initially offered price during its trading debut in the nation's largest first share sale in three years.
The stock soared 159% from the IPO price in Seoul, boosting its market cap to 9.9 trillion won ($8.2 billion). SK Biopharmaceuticals now has the largest equity value among health-care stocks trading in the South Korea after Samsung Biologics Co., Celltrion Inc and Celltrion Healthcare Co.
Biotech stocks have boomed in Korea since regulators banned short-selling on March 16 for six months amid the global pandemic selloff. Many of the firms surged after announcing plans to develop treatments related to Covid-19, making them favorites of the nation's retail traders.
Gains in the sector were rapid enough to prompt a $3 billion U.S. hedge fund to warn last week that valuations of Korean healthcare stocks --- trading at 80 times 12-month forward earnings -- are too expensive, leaving prices vulnerable.
Read more: Hedge Fund Sounds Alarm on Korea's $100 Billion Bio Stocks
More than $30 million in sales this year are expected from SK's pipelines, which include one drug under clinical trial for a rare disease and two FDA-approved ones -- Solriamfetol for excessive sleepiness and Cenobamate for epilepsy, according to Han Byung-hwa, analyst at Eugene Investment & Securities. That means the stock is trading at more than 200 times estimated sales, a high valuation given that rival UCB SA had a price-sales-ratio of 5 when it started its pharmaceutical business, Han wrote in a note.
Still, sales growth from the three drugs will be about 45% per year, reaching 1.8 trillion won in 2030, he added. Despite high R&D and marketing costs -- at least 200 billion won a year, the firm can get SK Group's support, he said.
SK Biopharmaceuticals is seeking 55% insurance coverage in the U.S. in July for cenobamate, brand-named Xcopri, without a partnership with local companies, CEO Jeong Woo Cho said at a press conference on June 15. Xcopri is about $30 per pill for 50 mg, compared with $20 per pill for rival UCB's Briviact's treatment, according to First Data Bank. UCB's Vimpat will go generic in 2022.
©2020 Bloomberg L.P.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
